Neuropharm Group plc
Fetcham Park House
Lower Road
Leatherhead
Surrey
KT22 9HD
United Kingdom
Tel: 44-0-1372-371-171
Website: http://www.neuropharm.co.uk/
7 articles about Neuropharm Group plc
-
Mydecine Innovations Group Featured in Forbes for the First-Of-Its-Kind Clinicals Using Psilocybin Therapy For PTSD
8/13/2020
Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company"), is pleased to announce that NeuroPharm Inc., a company focused on developing unique mental health therapies and approaches for veteran wellness, was recently covered in Forbes for its ground-breaking psilocybin clinical trials for treatment of posttraumatic stress disorder (PTSD). Conducted in collaboration with Leiden University Medical Center of
-
Neuropharm Group plc to Mull Voluntary Liquidation to Return Cash
3/10/2010
-
Neuropharm Group plc Sees Deal for Lead Drug, Shares Jump
5/28/2009
-
Neuropharm Group plc Shares Plunge as Lead Drug Misses
2/18/2009
-
Neuropharm Group plc - US Appointment
1/20/2009
-
Neuropharm Group plc Release: First Patients Treated In EMMA, The Follow-On Study To SOFIA
12/2/2008
-
Neuropharm Group plc Release: Appointment of President US Operations
2/26/2008